A llogeneic hematopoietic cell transplantation (allo-HCT) has been a potentially curative option for many patients with hematologic malignancies, acquired aplastic anemia, and selected inherited blood or immune disorders. In patients with hematologic malignancies, allo-HCT has been initially designed as a way to administer supralethal doses of total body irradiation (TBI). 1 However, an important part of the efficacy of the procedure is mediated by the destruction of recipient tumor cells by donor T cells present in the graft (graft-versus-tumor effects). [2] [3] [4] [5] Unfortunately, donor immune cells present in the graft can also target recipient ABBREVIATIONS: allo-HCT = allogeneic hematopoietic cell transplantation; APC = allophycocyanin; BM = bone marrow; HR = hazard ratio; PB = peripheral blood; TBI = total body irradiation; TREC(s) = T-cell receptor excision circle(s); Treg = regulatory T cells.
tissues, causing graft-versus-host disease (GVHD), a lifethreatening complication of allo-HCT. 6, 7 The first year after allo-HCT, establishment of graft-versus-host tolerance has been successful in 30% to 70% of the patients given unmanipulated grafts from HLA-matched donors, while the remaining patients experience chronic GVHD. 8, 9 It has been recognized since the late 1970s that tolerance after allogeneic allo-HCT was largely due to "a suppressor cell population" responsible for preventing GVHD by blocking sensitization of donor T cells against the host.
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Regulatory T cells (Treg) play a critical role in the maintenance of tolerance to self-antigens. 11, 12 Their development and function require transcription factor FOXP3. In humans, mutations in the FOXP3 gene cause Treg deficiency, and a fatal disorder characterized by immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX). 13 In the past decade, much attention has been paid to the potential role of Treg after allo-HCT. In murine experimental GVHD models, administration of high doses of Treg at the time of transplantation prevented acute GVHD without apparently impairing graft-versus-tumor effects. [14] [15] [16] Because thymic generation of Treg was markedly impaired, the majority of Treg the first month after allo-HCT in humans originated from expansion of mature Treg contained in the graft and exhibited an activated or memory phenotype. 17 In addition, Treg from patients with extensive chronic GVHD had low telomerase activity, suggesting that failure to activate Treg telomerase activity after allo-HCT could restrict their proliferative capacity and increase their susceptibility to apoptosis, resulting in low Treg number and the development of chronic GVHD. 18 These observations are in line with studies demonstrating a relative Treg deficit in the gut (but not in the stomach 19 ) of patients with GVHD compared to patients without GVHD 20 and an association between low Treg numbers and acute and/or chronic GVHD. 21 In addition, Treg infusion allowed safe infusion of an otherwise lethal dose of conventional T cells in the haploidentical allo-HCT setting 22 and possibly decreased acute GVHD in adult patients given double unrelated cord blood transplantation after reduced-intensity conditioning. 23 We and others have recently developed a model of xenogeneic GVHD, by infusing human peripheral blood mononuclear cells (PBMNCs) into NOD-scid interleukin (IL)-2Rg null (NSG) mice. 24 In that model, the severity of GVHD was closely correlated with the dose of PBMNCs infused. Here, we investigated the impact of infusion of clinical-grade enriched Treg on the development of xenogeneic GVHD in NSG mice.
MATERIALS AND METHODS

PBMNC collection and Treg enrichment
Before PBMNC collection, each volunteer donor (n = 6) underwent medical evaluation to assess his or her ability to donate and to explain the apheresis procedure. Each donor signed written informed consent (previously approved by the ethics committee of the CHU of Liege) for undergoing a leukapheresis for research purposes according to the standard operating procedures of the Laboratory of Cell and Gene Therapy. Leukapheresis procedures were performed using peripheral catheters and a continuous-flow blood cell separator (Cobe Spectra, Terumo BCT, Lakewood, CO) and according to a MNC collection protocol. The processed blood volume was approximately 2 total blood volumes. Anticoagulation was performed with ACD-A (ratio 1:12).
Treg were isolated using a system for clinical-gradeconform large-scale cell separations (CliniMACS system, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Clinical-grade reagents were used. CD4+CD25+ Treg were isolated in a two-phase procedure: simultaneous CD8 and CD19 depletion followed by CD25-positive selection. In the first phase, cells were washed, adjusted to 87.5 mL in phosphate-buffered saline (PBS)-ethylenediaminetetraacetic acid (EDTA)-0.5% human serum albumin (HSA), labeled with CliniMACS CD8 and CD19 reagents (Miltenyi Biotec) for 30 minutes at room temperature on an orbital shaker, rewashed, and resuspended in 100 to 300 mL of PBS-EDTA-0.5% HSA (concentration on the CliniMACS had to be below 4 ¥ 10 8 cells/mL). CD8-and CD19-labeled cells were depleted by the 2.1 depletion program of the CliniMACS instrument (Miltenyi Biotec). After being washed, the CD8 neg CD19
neg cell fraction was suspended in 380 mL of PBS-EDTA-0.5% HSA, labeled with CD25 reagents (Miltenyi Biotec) for 15 minutes at 4°C on an orbital shaker, washed, and resuspended in 100 mL of PBS-EDTA-0.5% HSA. CD25+ cells were isolated by automatic positive-selection cycles using the 3.1 enrichment program on the CliniMACS plus device. Aliquots before and after each labeling, depletion, and enrichment step were immunophenotyped.
Flow cytometry analyses for Treg enrichment
Analysis of cell surface molecules was performed by multicolor staining at each step of the cell separation process using the CliniMACS plus system (first step of double CD8/ CD19 depletion-apheresis product, start product before CD8/CD19 depletion, discarded and depleted fractions; second step of CD25-positive selection-start fraction, positive [Treg-enriched] and negative fractions). The following antibodies specific for human cell surface antigens were used: CD45-VioBlue, CD8-allophycocyanin (APC), CD15-phycoerythrin (PE), CD14-PE, CD20 
Suppression assay
For the last two selection procedures, Treg function was assessed with a 7-hour flow cytometric assay, using suppression by Treg of the activation markers CD69 and CD154 on responder T cells (CD4+CD25-; activated with anti-CD3/CD28-coated beads [Dynabeads, Invitrogen, Gent, Belgium] at a bead/responder T-cell ratio of 0.2), as described by Canavan and coworkers. 
Signal-joint T-cell receptor excision circles
Naive (CD4+CD25+CD127-CD45RA+CCR7+) and memory (CD4+CD25+CD127-CD45RA-) Treg were isolated from the Treg-enriched fraction of Donor 5 by a cell sorter (FACS ARIA II, Becton Dickinson). Quantification of signal-joint T-cell receptor excision circles among naive and memory Treg was assessed as previously described.
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Assessment of demethylated FOXP3il sequences
Genomic DNA was prepared from the enriched Treg fractions with the PureLink genomic DNA mini kit (Invitrogen). One microgram of genomic DNA was treated with sodium bisulfite using a bisulfite conversion kit (EpiTect, Qiagen, Düsseldorf, Germany). Real-time polymerase chain reaction (PCR) amplification of methylated and demethylated FOXP3i1 sequences was performed on 62.5 ng of bisulfite-converted DNA as previously described, 28 with methyl-specific primers listed by Lucas and coworkers. 29 The proportion of cells with demethylated FOXP3i1 was calculated as follows: (number of demethylated FOXP3i1 sequences/(number of demethylated FOXPi1 sequences + number of methylated FOXP3i1 sequences)) ¥ number of X chromosomes per cell. The calculated proportions are approximate, because the methylation-specific quantitative PCR assay detects only sequences that are either completely demethylated or completely methylated in the FOXP3i1 region.
Induction of xenogeneic GVHD in NSG mice
All experimental procedures and protocols used in this investigation were reviewed and approved by the Institutional Animal Care and Use Ethics Committee of the University of Liège, Belgium (Permit 711). The "Guide for the Care and Use of Laboratory Animals," prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press, was followed carefully. NSG mice (The Jackson Laboratory, Bar Harbor, ME) were given 2.5 Gy TBI using a 137 Cs source 1 day before IV injection of either 2 ¥ 10 6 human PBMNCs (apheresis product, PBMNC group) alone, IV injection of 2 ¥ 10 6 human PBMNCs (apheresis product) plus 1 ¥ 10 6 CD4+CD25 enriched Treg (PBMNC + Treg group), or IV injection of 2 ¥ 10 6 enriched Treg alone (Treg group). Each group included from five to seven mice depending on the number of NSG mice available. All cell products were infused fresh. In the first experiment, two doses of enriched Treg were tested (0.5 ¥ 10 6 and 1 ¥ 10 6 CD4+CD25 enriched Treg). In the fourth experiment, all cell doses were doubled. In Experiments 2 through 6, one mouse in each of the three groups (PBMNCs only, PBMNCs + Treg, and Treg only) was selected before transplant to be sacrificed around Day 26 (range, Days 25-27) to allow flow cytometric analyses. In Experiment 4, all mice in the PBMNC-only and the PBMNC + Treg groups died before Day 26 (and thus no mouse could be euthanized on Day 26) . Further, in Experiments 3 and 6, the mice in the PBMNC group scheduled for necropsy on Day 26 died earlier and were then replaced randomly by two other PBMNC mice. Mice who suffered from terminal stage of xenogeneic GVHD were euthanized.
Detection of human engraftment by flow cytometry
At the time of necropsy, peripheral blood (PB), spleen, and bone marrow (BM) were harvested and analyzed by flow cytometry. Splenocytes were obtained by crushing the spleen, and BM cells by flushing femurs and tibiae. Cells were counted in a hematology analyzer (XS-800i, Sysmex, Hoeilaart, Belgium). The PB was depleted of red blood cells using the RBC lysis buffer (eBiosciences) according to the manufacturer's instructions. The following antibodies specific for human cell surface antigens were used: Horizon v500-conjugated anti-CD3 (SP34-2 
Histology and immunochemistry
Lungs from mice euthanized on Days 25 to 27 after transplantation (one mouse in each group from Experiments 2, 3, 5, and 6) were harvested, washed with PBS, fixed in 10% formalin (Sigma Aldrich), and routinely processed for paraffin embedding. Five-micrometer sections were stained with hematoxylin-eosin for histologic examination. Xenogeneic GVHD in lung sections was assessed in a semiquantitative fashion as described by Nervi and colleagues. 30 
Statistical analyses
The Mann-Whitney test was used to compare homing receptor expression between naive and memory Treg and between lymphocyte subsets at necropsy in mice from different groups. Survival curves were modeled using the Kaplan-Meier methods. Comparisons between groups were made with the log-rank test. 
Treg coinfusion delayed experimental xenogeneic GVHD
As previously observed, 24 the timing of GVHD occurrence varied from donor to donor (Fig. 1) In the first experiment, we also tested two ratios of PBMNCs/Treg (2/1 and 4/1), and as shown in Fig. 1A , there was no difference in survival between the two ratios (median survival 56 days vs. 55 days). In the sixth cohort, Tregenriched coinfusion failed to delay experimental xenogeneic GVHD (the median survival was 46 days in the PBMNC group vs. 48 days [p = 0.337] in the PBMNC + Treg group). This could be related to the low purity of the Tregenriched fraction due to a technical problem (see above) that also resulted in a higher number of conventional PBMNCs infused. Nevertheless, in the Cox model taking into account data from the six experiments, survival remained significantly higher in the PBMNC + Treg group than in the PBMNC group (HR, 0.34; 95% CI, 0.19-0.62; p = 0.0004).
In Experiments 2, 3, 5, and 6 (in Experiment 4, mice died before Day 26), one mouse from each of the PBMNC, PBMNC + Treg, and Treg groups (each selected before transplantation) were euthanized on Days 25 to 27 (depending on experiments, median Day 26.5) after transplantation. There were no significant differences between the PBMNC and the PBMNC + Treg groups for infiltration by human CD45+CD3+ cells in the blood ( 10 .9%] in the PBMNC + Treg group). The frequency of T-cell subsets (CD4 and CD8) as well as their mitotic activity (assessed by KI67 expression) in the PB, spleen, and BM were comparable in PBMNC and PBMNC + Treg mice ( Fig. 2A-C) . Interestingly, the frequency of Foxp3+ cells among total (Fig. 2D) . Finally, histologic signs of xenogeneic GVHD in the lungs on Day 26 were similar in the PBMNC and PBMNC + Treg groups (Table 2) and were relatively mild, probably because histology was performed relatively soon after transplantation.
Fate of Treg-enriched fraction infused alone in NSG mice
Infusion of the Treg-enriched fractions in NSG mice given 2.5 Gy TBI on Day -1 was safe with only one of 21 mice dying during the study period (>120 days after transplantation) of unknown cause and none of the mice experiencing clinical GVHD ( Figs. 3 and 4A ; there was, however, some histologic evidence of lung GVHD in Treg mice scheduled to be euthanized on Day 26). In Experiments 2, 3, 5, and 6, one mouse (selected before transplantation) was euthanized between Days 25 and 27 (median, Day 26.5) after transplantation. At necropsy, infiltration by human CD45+CD3+, CD45+CD3+CD4+, and CD45+CD3+CD8+ cells was, respectively, 0.5% (range, 0.3%-8.1%), 0.4% (range, 0.3%-7.9%), and 0% (range, 0%) in the blood; 0.6% (range, 0.4%-13.4%), 0.2% (range, 0%-12.1%), and 0.4% (range, 0.2%-0.7%) in the spleen; and 0.2% (range, 0.2%-1.3%), 0.2% (range, 0%-1.1%), and 0% (range 0%-0.1%) in the BM. Interestingly, the percentage of CD25+Foxp3+ cells among total human CD45+CD3+CD4+ cells was very low, that is, 2.1% (range, 1.9%-12.5%) in the spleen, 3.1% (range, 0.5%-3.2%) in the BM, and 12.2% (range, 1%-24.9%) in the blood (Fig. 4B) . Further, among CD4+ T cells in the spleen, the vast majority of CD4+ T cells were memory CD4+ T cells (median, 97%; range, 84%-97%).
The remaining mice were euthanized at the end of the study period (124-166 days after transplantation). Infiltrations by human CD45+CD3+, CD45+CD3+CD4+, and CD45+CD3+CD8+ cells were, respectively, 0.2% (range, 0%-12.6%), 0.7% (range, 0%-6.5%), and 0% (range, 0%-2.6%) in the blood; 2.9% (range, 0.1%-51.1%), 1.1% (range, 0%-34.5%), and 0.6% (range 0%-4.7%) in the spleen; and 0.2% (range, 0%-5.6%), 0.15% (range, 0%-4.4%), and 0% (range, 0-0.7%) in the BM. 
DISCUSSION
Treg infusion is one of the most promising nonpharmacologic approaches for GVHD prevention or treatment. However, isolating a pure population of Treg in sufficient amount for clinical use has remained challenging (outside of the HLA-haploidentical setting where very few conventional T cells are transplanted). 16, 22, 31, 32 Some groups of investigators are focusing their research on ex vivo Treg expansion. 23, 31 While this approach could yield sufficient Treg numbers with very good purity when mTor inhibitors are added to the culture media, the fate of ex vivo expanded Treg after infusion in humans has remained poorly understood, although Brunstein and colleagues 23 could detect ex vivo expanded (without mTor inhibition) Treg in the PB up to 14 days after infusion in the context of unrelated cord blood transplantation. Further potential limitations of Treg ex vivo expansion include reduction in their T-cell repertoire, as well as possible expansion of Th17 cells when ex vivo expansion is carried out without mTor inhibitors. 33 In addition, given that mTor inhibitors also induce FoxP3 on conventional T cells, 34 Treg ex vivo expansion in the presence of mTor inhibitors does not exclude the risk of a contamination by induced Treg that could revert in vivo, in the absence of in vivo mTor inhibition. 31 Thus, another approach might consist of infusing a less pure population of freshly isolated Treg (obtained by clinical-grade immunomagnetic selection), 35, 36 followed by in vivo selection or expansion with sirolimus and/or low-dose IL-2, 37,38 thus avoiding the need for culturing Treg ex vivo in good manufacturing practice conditions. However, before proposing this easier approach to patients with steroid-refractory chronic GVHD, we wanted to investigate the ability of clinical-grade enriched Treg to attenuate experimental xenogeneic GVHD induced by PBMNC (autologous to Treg) infusion in NSG mice. Given that the purity of the enriched fraction was not 100%, it was also necessary to verify their inability to induce xenogeneic GVHD when infused alone. Several observations were made.
First, this report confirms the chosen combined negative and positive separation strategy to select Treg performed by using the CliniMACS plus system (device and reagents) allows recovery of a large number of enriched CD4+CD25+FoxP3+ T cells, with a median purity ranging from 42% to 68%. This is in line with what was observed by other groups of investigators. 22 Interestingly, we also demonstrated in sorted cells from Donor 5 that naive Treg (in comparison to memory Treg) were markedly enriched for recent thymus emigrants expressing more than 20 times more TRECs per 10 5 cells. Second and more importantly, coinfusion of enriched Treg at a PBMNC/Treg-enriched ratio of 2/1 (with a real non-Treg/Treg [defined as CD4+CD25
high FoxP3+] ratio ranging from 2.5 to 3.3) delayed the development of xenogeneic GVHD and prolonged survival. These results are in line with two previous reports demonstrating that coinfusion of fresh CD25+ T cells or of expanded Treg (with a purity of 70%) attenuated xenogeneic GVHD caused by infusion of PBMNCs (autologous to Treg) in another deficient mouse strain (Rag2-/-gammaC-/-mice). 39, 40 Our results are also in line with those observed by Hippen and colleagues 41 and by Chakraborty and colleagues 42 who demonstrated that coinfusion of expanded Treg at a PBMNC/Treg ratio of 1/1 decreased xenogeneic GVHD and increased survival of NSG mice. The originality of our work in comparison with those previous reports is that we used freshly isolated Treg (using clinical-grade compliant method) and not expanded Treg. Although Treg-enriched infusion attenuated xenogeneic GVHD in our study, they only provided a temporary protection from xenogeneic GVHD since most mice who survived beyond Day 75 after PBMNC/Treg coinfusion eventually developed signs of "xenogeneic chronic GVHD" (skin fibrosis and hair loss [ Fig. 3] ). This could be due to a larger expansion of conventional T cells compared to that of Treg in our model (in line with the apparent disappearance of Treg when infused alone in NSG mice) or to the fact that we used a suboptimal ratio of PBMNC/Treg (for example the PBMNC/Treg ratio in the study by Di Ianni and coworkers 22 was 1/2 instead of 2/1 in current study). Further studies are needed to assess whether approaches combining Treg infusion with rapamycin or low-dose IL-2 will allow to totally abrogate xenogeneic GVHD in this model and to assess the impact of Treg infusion on engraftment of human hematopoietic stem/ progenitor cells in NSG mice.
Third, infusion of the Treg-enriched fraction alone did not induce xenogeneic GVHD, even in the sixth cohort where Treg purity was only 42% and mice thus received more than 1 ¥ 10 6 conventional CD4+ T cells. Interestingly, cells from Treg-enriched fractions when infused alone not only did not cause GVHD, but also did not expand (or if they expanded underwent apoptosis), as shown by the very low human cell infiltration in NSG mice observed at necropsy. A probable explanation is that Treg inhibited in vivo the conventional activated CD4+ T cells contained in the Treg-enriched fraction, while true Treg did not expand probably due to a lack of human IL-2 in that model when only enriched Treg are infused, as observed in a recent report from Abraham and colleagues. 43 Further, clinical studies have demonstrated that, after allo-HCT, infusion of CD8-depleted donor lymphocytes induced less acute GVHD than infusion of unmanipulated DLI, 44 suggesting that CD4+ T cells were less prone to induce GVHD than CD8+ T cells in humans.
In summary, our data suggest that infusion of clinicalgrade enriched Treg delayed the occurrence of xenogeneic GVHD induced by human autologous PBMNCs (at a PBMNC/enriched Treg ratio of 2/1) in NSG mice, at least when Treg purity in the Treg-enriched fraction was more than 55%. Based on these results, a pilot study of CliniMACS-enriched donor Treg infusion together with in vivo selection with rapamycin is under development as treatment for patients with steroid-refractory chronic GVHD.
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